Extended‐Release Oral Milrinone for the Treatment of Heart Failure With Preserved Ejection Fraction

Background Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent form of heart failure, representing half of the total burden of heart failure. We hypothesised that modulation of the phosphodiesterase type 3/cyclic AMP using a novel oral formulation of milrinone might e...

詳細記述

書誌詳細

出版年:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
主要な著者:	Shane Nanayakkara, Melissa Byrne, Vivian Mak, Kaye Carter, Eliza Dean, David M. Kaye
フォーマット:	論文
言語:	英語
出版事項:	Wiley 2020-07-01
主題:	diastolic heart failure inotropes lusitropy pharmacotherapy phosphodiesterase type 3
オンライン･アクセス:	https://www.ahajournals.org/doi/10.1161/JAHA.119.015026